NCT01406132

A Study to Assess the Pharmacokinetics of ASP015K in Healthy Male Subjects

A Phase 1, Open-Label, Mass Balance Study to Evaluate the Pharmacokinetics of ASP015K After a Single Oral Dose of 14C-Labeled ASP015K in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The objective of this study is to evaluate pharmacokinetics, in particular the routes of excretion and extent of metabolism of ASP015K after a single oral dose of 14C-labeled ASP015K.

Detailed description

Eligible subjects will be admitted to the clinical research unit and confined for a minimum of 8 days.

Conditions

• Healthy Subjects
• Pharmacokinetics of ASP015K

Interventions

Type	Name	Description
DRUG	ASP015K	oral

Timeline

• Start date: 2009-12-01
• Primary completion: 2010-01-01
• Completion: 2010-01-01
• First posted: 2011-08-01
• Last updated: 2011-08-01

Locations

1 site across 1 country: United States